CA2685599A1 - Composes pour traiter la dystrophie musculaire de duchenne - Google Patents

Composes pour traiter la dystrophie musculaire de duchenne Download PDF

Info

Publication number
CA2685599A1
CA2685599A1 CA002685599A CA2685599A CA2685599A1 CA 2685599 A1 CA2685599 A1 CA 2685599A1 CA 002685599 A CA002685599 A CA 002685599A CA 2685599 A CA2685599 A CA 2685599A CA 2685599 A1 CA2685599 A1 CA 2685599A1
Authority
CA
Canada
Prior art keywords
thiazole
imidazo
alkyl
nr4c
methylimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002685599A
Other languages
English (en)
Inventor
Graham Michael Wynne
Stephen Paul Wren
Paul Damien Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin IGA Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0714303A external-priority patent/GB0714303D0/en
Priority claimed from GB0803906A external-priority patent/GB0803906D0/en
Application filed by Individual filed Critical Individual
Publication of CA2685599A1 publication Critical patent/CA2685599A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte sur des composés représentés par la formule générale (I) dans laquelle X1, X2, X3, R1, R2, R3, Y et Z sont tels que définis dans le descriptif. Lesdits composés s'utilisent pour le traitement et la prévention de la dystrophie musculaire de Duchenne, de la dystrophie musculaire de Becker et de la cachexie.
CA002685599A 2007-07-23 2008-07-21 Composes pour traiter la dystrophie musculaire de duchenne Abandoned CA2685599A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0714303.5 2007-07-23
GB0714303A GB0714303D0 (en) 2007-07-23 2007-07-23 Use of compounds for preparing anti-tuberculosis agents
GB0803906A GB0803906D0 (en) 2008-03-03 2008-03-03 Compounds for treating duchenne muscular dystrophy
GB0803906.7 2008-03-03
PCT/GB2008/002495 WO2009013477A1 (fr) 2007-07-23 2008-07-21 Composés pour traiter la dystrophie musculaire de duchenne

Publications (1)

Publication Number Publication Date
CA2685599A1 true CA2685599A1 (fr) 2009-01-29

Family

ID=39884469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002685599A Abandoned CA2685599A1 (fr) 2007-07-23 2008-07-21 Composes pour traiter la dystrophie musculaire de duchenne

Country Status (5)

Country Link
EP (1) EP2167508A1 (fr)
JP (1) JP2010534231A (fr)
AU (1) AU2008278824A1 (fr)
CA (1) CA2685599A1 (fr)
WO (1) WO2009013477A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624610T3 (es) * 2003-04-11 2017-07-17 Ptc Therapeutics, Inc. Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2007019417A1 (fr) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Dérivés d’oxazolopyridine comme modulateurs du sirtuin

Also Published As

Publication number Publication date
AU2008278824A1 (en) 2009-01-29
JP2010534231A (ja) 2010-11-04
WO2009013477A1 (fr) 2009-01-29
EP2167508A1 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
KR101472248B1 (ko) 뒤시엔느 근이영양증의 치료
JP2022506887A (ja) 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
WO2008029152A2 (fr) Traitement de la dystrophie musculaire de duchenne
AU2013358591B2 (en) Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
US20120149741A1 (en) Treatment of duchenne muscular dystrophy
EP3148539B1 (fr) Inhibiteurs d'histone désacétylase, et compositions et méthodes d'utilisation de ceux-ci
KR20090005296A (ko) 뒤시엔느 근이영양증의 치료
WO2014159214A1 (fr) Inhibiteurs d'histone désacétylase, et compositions et méthodes d'utilisation de ceux-ci
AU2018200421A1 (en) Naphthyridinedione derivatives
CA2955059A1 (fr) Derives de spiroquinoxaline en tant qu'inhibiteurs de la mort cellulaire regulee non apoptotique
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
JP7110325B2 (ja) インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤
CA3087807A1 (fr) Inhibteurs de l'indoleamine 2,3-dioxygenase et/ou du tryptophane dioxygenase
EP3152208B1 (fr) Pyrimido [4,5-b]quinoline-4,5(3h, 10h)-diones comme suppresseur de mutations non-sens
CA2685599A1 (fr) Composes pour traiter la dystrophie musculaire de duchenne
JP2017516829A (ja) ピリドピリミジンジオン誘導体
JP2024072283A (ja) Ａｈｒアゴニスト

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20120723